ctk3 Antibody

What is the CT-3 antibody and what epitope does it recognize?

The CT-3 antibody is a Mouse (BALB/c) IgG1κ monoclonal antibody that specifically recognizes the CD3 protein complex in chicken and pigeon T cells. It targets a complex of at least three polypeptides with molecular weights of 20, 19, and 17 kDa, two of which are N-glycosylated. Additionally, when used with digitonin-solubilized T cell lysates, the antibody coprecipitates a polypeptide of 90 kDa that can be reduced to two polypeptides of 50 and 40 kDa under reducing conditions. The antibody recognizes a key component of the T cell receptor-associated complex, also known as the T3/TCR complex .

What are the validated research applications for CT-3 antibody?

The CT-3 antibody has been validated for multiple research applications in avian immunology:

This antibody serves as a valuable tool for studying T cell development, activation, and function in avian models, which are important for comparative immunology research .

How should I optimize CT-3 antibody concentration for flow cytometry applications?

When optimizing CT-3 antibody concentration for flow cytometry, a titration approach is recommended to determine the optimal signal-to-noise ratio. Begin with a concentration range of 0.1-10 μg/mL and evaluate results with appropriate positive controls (chicken thymocytes or peripheral blood T cells) and negative controls (B cells or non-avian cells). The antibody's recommended storage is at 2-8°C, and working dilutions should be prepared fresh before use.

For best results, use a buffer containing 1-2% bovine serum albumin (BSA) or fetal bovine serum (FBS) in phosphate-buffered saline (PBS) to reduce non-specific binding. If background staining persists, consider including a blocking step with 10% normal mouse serum. The CT-3 antibody can be used in combination with other avian lymphocyte markers to create comprehensive immunophenotyping panels .

What controls should be included when using CT-3 antibody in immunohistochemistry experiments?

For rigorous immunohistochemistry experiments with CT-3 antibody, the following controls are essential:

• Isotype control: Use Mouse IgG1-UNLB (15H6) at the same concentration as the CT-3 antibody to assess non-specific binding

• Positive tissue control: Include chicken thymus or spleen sections where CD3+ T cells are abundant

• Negative tissue control: Include tissues known to lack T cells (e.g., chicken bursa of Fabricius which is primarily B cells)

• Absorption control: Pre-incubate the antibody with purified chicken CD3 protein prior to staining

• Secondary antibody control: Omit primary antibody to assess non-specific binding of the detection system

For frozen sections, optimal fixation with 4% paraformaldehyde for 10 minutes is recommended, while paraffin sections require antigen retrieval, typically using citrate buffer (pH 6.0) under heat and pressure .

How can I assess the outcome accuracy of CT-3 antibody in microarray experiments?

To evaluate the accuracy of CT-3 antibody in microarray experiments, implement a dual-fluorescence labeling approach as described in experimental quality control protocols. This method involves:

• Divide your protein sample into two equal aliquots

• Label one aliquot with Cy3 and the other with Cy5

• Prepare two microarray slides with the following compositions:

  • Slide #1: Incubate with a mixture containing 33.334 μg of Cy3-labeled proteins and 16.667 μg of Cy5-labeled proteins

  • Slide #2: Incubate with a mixture containing 33.334 μg of Cy5-labeled proteins and 16.667 μg of Cy3-labeled proteins

• Calculate the ratio for each spot using the formula:

  $R_i = \frac{F_{Cy3,i,1}/F_{Cy5,i,1}}{F_{Cy5,i,2}/F_{Cy3,i,2}}$

Where $F_{Cy3,i,1}$ represents the Cy3 fluorescence intensity at spot i on slide 1, and similar notation applies to other measurements.

With the protein ratios maintained at 2:1 (Cy3:Cy5) in slide #1 and 1:2 (Cy3:Cy5) in slide #2, the theoretical outcome ratio should be $R_i = 2$. Significant deviations from this expected ratio indicate potential issues with antibody specificity, cross-reactivity, or experimental conditions .

What methods can verify the specificity of CT-3 antibody binding to chicken CD3?

To verify the specificity of CT-3 antibody binding to chicken CD3, employ multiple complementary approaches:

• Western blot analysis: Perform under both reducing and non-reducing conditions to confirm detection of expected molecular weight proteins (20, 19, and 17 kDa polypeptides)

• Immunoprecipitation followed by mass spectrometry: Use CT-3 antibody to precipitate proteins from chicken T cell lysates, then identify the precipitated proteins by mass spectrometry to confirm they match chicken CD3 components

• Competitive binding assays: Pre-incubate CT-3 antibody with purified chicken CD3 protein prior to staining or immunoprecipitation to demonstrate specific blocking of binding

• Knockdown validation: Use siRNA to knock down CD3 expression in chicken cell lines, then demonstrate reduced binding of CT-3 antibody

• Cross-species reactivity testing: Test CT-3 antibody against T cells from various species to confirm its specificity to chicken/pigeon CD3 over other avian or mammalian CD3 proteins

These approaches collectively provide strong evidence for antibody specificity when positive results align with the known molecular characteristics of chicken CD3 .

How can CT-3 antibody be utilized in multiparametric flow cytometry for avian T cell subset analysis?

For sophisticated multiparametric analysis of avian T cell subsets, CT-3 antibody can be integrated into comprehensive panels using the following methodology:

• Panel design considerations:

  • Use CT-3 as a pan-T cell marker alongside subset-specific markers

  • Select fluorophores with minimal spectral overlap (e.g., FITC, PE, APC, PE-Cy7)

  • Include viability dye to exclude dead cells

  • Add FC receptor blocking step to reduce non-specific binding

• Recommended T cell subset panel:

• Gating strategy:

  • Gate on lymphocytes based on FSC/SSC

  • Exclude doublets using FSC-A/FSC-H

  • Select viable cells (negative for viability dye)

  • Gate on CD3+ cells

  • Further analyze CD4+, CD8+, and double-positive/double-negative populations

  • Examine γδ TCR expression and CD44 to identify memory subsets

This approach allows precise identification and quantification of T cell subpopulations in avian samples, facilitating advanced immunological research in these model systems .

Can CT-3 antibody be incorporated into engineered bispecific or trispecific constructs for advanced immunotherapy research?

Yes, CT-3 antibody can be engineered into multispecific constructs for cutting-edge immunotherapy research, following established principles of therapeutic antibody engineering:

• Bispecific format options:

  • 1+1 common light chain format (one arm targeting CD3, one arm targeting tumor antigen)

  • CrossMab technology to ensure correct light chain pairing

  • Knob-into-Hole mutations for heavy chain heterodimerization

• Trispecific format considerations:

  • 2+1 format with CD3-binding Fab positioned internally between two targeting arms

  • N-terminal fusion of additional specificity (e.g., checkpoint inhibitor)

  • Strategic positioning of immune-engaging moiety (CD3) in the "inner" position for improved safety profile

• Production and validation approach:

  • Clone constructs using Golden Gate Cloning method

  • Express in Expi293F cells or similar mammalian expression system

  • Purify using sequential IMAC and StrepTactin XT chromatography

  • Validate assembly by SDS-PAGE under reducing and non-reducing conditions

  • Confirm functional binding to all targets with appropriate binding assays

Such engineered constructs could potentially bridge avian T cells with target cells, creating novel research tools for studying T cell activation mechanisms or developing veterinary immunotherapeutics .

How should I address inconsistent staining with CT-3 antibody in immunohistochemistry?

When encountering inconsistent staining with CT-3 antibody in immunohistochemistry, systematically investigate and address the following factors:

• Tissue fixation and processing:

  • Overfixation may mask epitopes - limit fixation time to 12-24 hours for formalin

  • For paraffin sections, ensure complete deparaffinization and thorough rehydration

  • Consider testing multiple antigen retrieval methods (heat-induced vs. enzymatic)

  • For frozen sections, test different fixation methods (acetone, methanol, paraformaldehyde)

• Antibody-specific factors:

  • Verify antibody viability by testing on positive control tissue known to express CD3

  • Titrate antibody concentration (0.5-10 μg/mL) to determine optimal concentration

  • Test longer primary antibody incubation (overnight at 4°C vs. 1 hour at room temperature)

  • Consider adding protein blockers (5% BSA or 10% normal serum) to reduce background

• Detection system:

  • Switch between detection methods (direct vs. indirect, polymer-based vs. avidin-biotin)

  • For challenging samples, try signal amplification systems (tyramide signal amplification)

  • Ensure secondary antibody is appropriate for the primary antibody isotype (IgG1κ)

• Sample-specific issues:

  • Test freshly collected tissues versus archived samples

  • Implement positive controls from the same processing batch

  • Assess endogenous peroxidase or phosphatase blocking efficiency

Methodically documenting each modification will help identify the critical variables affecting staining consistency for your specific tissue and application .

What strategies can address cross-reactivity concerns when using CT-3 antibody in complex samples?

To address potential cross-reactivity when using CT-3 antibody in complex biological samples, implement the following analytical strategies:

• Pre-absorption controls:

  • Incubate the antibody with purified chicken CD3 protein before application

  • Gradually increase the concentration of blocking protein to determine specificity threshold

  • Compare staining patterns between absorbed and non-absorbed antibody preparations

• Negative cell line controls:

  • Test the antibody on chicken B cell lines or non-lymphoid chicken cell lines

  • Include mammalian T cell lines as negative controls

  • Use CRISPR/Cas9 CD3 knockout cell lines as definitive negative controls

• Competitive binding assessment:

  • Perform sequential staining with different anti-CD3 antibodies that recognize distinct epitopes

  • Analyze blocking or non-blocking patterns to map epitope specificity

• Advanced validation techniques:

  • Mass cytometry (CyTOF) for highly multiplexed epitope analysis

  • Immunoprecipitation followed by mass spectrometry to identify all bound proteins

  • Surface plasmon resonance (SPR) to measure precise binding kinetics with purified antigens

By systematically employing these approaches, researchers can confidently determine the specificity profile of CT-3 antibody and interpret results appropriately, even in samples with potential cross-reactive proteins .

How might the CT-3 antibody be adapted for use in advanced imaging techniques beyond conventional microscopy?

The CT-3 antibody can be strategically modified for implementation in cutting-edge imaging technologies through several approaches:

• Super-resolution microscopy adaptations:

  • Direct conjugation to photo-switchable fluorophores (e.g., Alexa 647) for STORM imaging

  • Modification with small organic dyes compatible with STED microscopy

  • Combination with click chemistry-compatible tags for in situ visualization

• In vivo imaging applications:

  • Conjugation to near-infrared fluorophores for deep tissue penetration

  • Development of F(ab) or single-chain fragments to improve tissue distribution

  • Immobilization on nanoparticles alongside contrast agents for multimodal imaging

• Intravital microscopy optimization:

  • Create non-depleting variants that bind without affecting T cell function

  • Develop stable fluorophore conjugates resistant to photobleaching during long-term imaging

  • Pair with genetically encoded reporters in transgenic avian models

• Novel detection methods:

  • Adaptation for mass cytometry using metal isotope labeling

  • Coupling with quantum dots for multiplexed confocal applications

  • Integration with expansion microscopy protocols for improved subcellular visualization

These advanced imaging applications would enable researchers to visualize avian T cell dynamics with unprecedented spatial and temporal resolution, opening new avenues for understanding T cell biology in these important model organisms .

What approaches can integrate CT-3 antibody with systems biology methods for comprehensive T cell functional analysis?

Integrating CT-3 antibody with systems biology approaches enables comprehensive functional analysis of avian T cells through the following methodological frameworks:

• Multi-omics integration strategies:

  • Cell sorting using CT-3 for T cell isolation followed by transcriptomics (RNA-seq)

  • Coupling with phosphoproteomics to map TCR signaling cascades

  • Combining with epigenetic profiling (ATAC-seq, ChIP-seq) of sorted populations

  • Integration with metabolomics for understanding T cell metabolic states

• Single-cell analysis workflows:

  • Index sorting with CT-3 and linking to single-cell RNA-seq profiles

  • Spatial transcriptomics with CT-3 immunofluorescence for territorial context

  • CITE-seq approaches combining surface protein detection with transcriptomics

• Network biology applications:

  • Protein interaction studies using CT-3 immunoprecipitation coupled with mass spectrometry

  • Pathway analysis of differentially expressed genes in CT-3+ cells

  • Computational modeling of T cell receptor signaling networks in avian systems

• Functional systems approach:

  • CT-3-based stimulation coupled with cytokine secretion profiling

  • Integration with chicken cytokine arrays for comprehensive immune response analysis

  • Time-course studies capturing dynamic changes in T cell populations during immune responses

This systems immunology framework allows researchers to build comprehensive models of avian T cell biology, connecting molecular-level changes to functional outcomes and providing mechanistic insights into comparative immunology .